Skip to main content

Table 2 Effect size (Cohen’s D) between groups

From: Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4–5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial

Variables

Bumetanide plus placebo

Mean ± SD

Bumetanide plus chlorthalidone

Mean ± SD

p-value

Cohen's D

Changes of SBP

 7 day

-7.5 ± 17.8

-18.1 ± 14.1

0.073

0.66

 30 day

-10 ± 23.3

-26.2 ± 15.3

0.028

0.84

Changes of DBP

 7 day

-2.25 ± 8.6

-8.5 ± 9.3

0.059

0.69

 30 day

-3.40 ± 11.9

-13.5 ± 10.7

0.018

0.89

Changes of MAP

 7 day

-3.97 ± 10.2

-11.7 ± 8.7

0.029

0.82

 30 day

-5.41 ± 14.3

-18.1 ± 8.7

0.005

1.10

Changes of TBW

 7 day

-0.59 ± 2.38

-2.5 ± 1.9

0.016

0.89

 30 day

-0.07 ± 1.78

-5.3 ± 6.2

0.003

1.31

Changes of ECW

 7 day

-0.43 ± 1.4

-1.58 ± 0.69

0.007

1.10

 30 day

-0.15 ± 1.2

-3.11 ± 2.68

 < 0.000

1.52

Changes of ECW/TBW

 7 day

-0.72 ± 1.7

-1.24 ± 1.94

0.077

1.21

 30 day

-0.24 ± 1.4

-4.38 ± 6.49

0.018

1.05

Changes of FENA

 7 day

-0.19 ± 3.4

0.78 ± 0.82

0.284

0.28

 30 day

-0.35 ± 3.4

0.59 ± 2.29

0.371

0.08

Changes of BNP

 7 day

33.6 ± 178

-39.3 ± 110

0.174

0.04

 30 day

213.5 ± 669

-0.64 ± 146

0.221

0.52

  1. Abbreviations: SBP Systolic Blood Pressure, PAD Diastolic Blood Pressure, MAP Mean Arterial Pressure, TBW Total Body Water, ECW Extracellular Water, ECW/BTW Total Body Water/Extracellular Water Ratio, FENA Fraction Excretion Sodium, BNP Brain Natriuretic Peptide